Eli Lilly and Company (LLY)vsVirax Biolabs Group Limited Ordinary Shares (VRAX)
LLY
Eli Lilly and Company
$1,155.27
-4.55%
HEALTHCARE · Cap: $1.02T
VRAX
Virax Biolabs Group Limited Ordinary Shares
$2.93
+1.38%
HEALTHCARE · Cap: $3.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 581714876% more annual revenue ($72.25B vs $12,420). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
VRAX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+87.3%
Fair Value
$1.65
Current Price
$2.93
$1.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Revenue surging 685.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -230.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : VRAX
The strongest argument for VRAX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 685.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Bear Case : VRAX
The primary concerns for VRAX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while VRAX is a hypergrowth play — different risk/reward profiles.
VRAX carries more volatility with a beta of 1.33 — expect wider price swings.
VRAX is growing revenue faster at 685.0% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 33/100), backed by strong 35.0% margins and 55.5% revenue growth. VRAX offers better value entry with a 87.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Virax Biolabs Group Limited Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?